Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure

Journal of Nuclear Medicine

Volumn 45, Issue 2, 2004, Pages 155-163

  Kyuma, Michifumi ^a   Nakata, Tomoaki ^a   Hashimoto, Akiyoshi ^a   Nagao, Kazuhiko ^b   Sasao, Hisataka ^c   Takahashi, Toru ^a   Tsuchihashi, Kazufumi ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sapporo Mental Clinic   (Japan)

^c Hakodate Goryokaku Hospital   (Japan)

Author keywords

Diabetes mellitus; Heart failure; Natriuretic peptides; Prognosis; Renal dysfunction; Sympathetic nervous system

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; BRAIN NATRIURETIC PEPTIDE; NITRIC ACID DERIVATIVE; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HEART DEATH; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; SYMPATHETIC INNERVATION; SYMPATHETIC NERVE; BLOOD; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; HEART; HEART STROKE VOLUME; INNERVATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; AGED; DIABETES MELLITUS; FEMALE; HEART; HEART FAILURE, CONGESTIVE; HUMANS; IODINE RADIOISOTOPES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME;

EID: 1542714258     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
2. Clerico A, Iervasi G, Del Chicca MG, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest. 1998;21:170-179.
3. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2002;106:2454-2458.
4. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
5. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38:955-962.
6. Nakata T, Wakabayashi T, Kyuma M, et al. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail. 2003;9:113-121.
7. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54.
8. Chidsey CA, Braunwald E, Morrow AC. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med. 1965;39:442-451.
9. Hasking GJ, Esler MD, Jennings GL, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-621.
10. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93:1667-1676.
11. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-477.
12. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579-590.
13. Wakabayashi T, Nakata T, Hashimoto A, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med. 2001;42:1757-1767.
14. Hunt HA, Baker DW, Chin MH, et al. American College of Cardiology/American Heart Association: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary - a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2001;104:2996-3007.
15. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
16. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988;78:1192-1199.
17. Mann DL, Kent RL, Parsons B, et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.
18. Ungerer M, Bohm M, Elce JS, et al. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation. 1993;87:454-463.
19. +, low pH, and adenosine: possible relevance to ischemia-induced denervation. Circ Res. 1990;66:289-301.
20. Barrett CJ, Schultz HD. Sympathoinhibitory effects of atrial natriuretic peptide in rats with heart failure. J Card Fail. 1999;5:316-323.
21. Abramson BL, Ando S, Notarius CF, et al. Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure. Circulation. 1999;99:1810-1815.
22. Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37:1221-1227.
23. Wijbenga AA, Balk AH, Jonkman FA, et al. Relation of atrial natriuretic peptides to left ventricular systolic and diastolic function in heart failure. Eur J Heart Fail. 1999;1:51-58.
24. Braunwald E, Colucci WS, Grossman W. Clinical aspects of heart failure: high-output heart failure - pulmonary edema. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: WB Saunders; 1997:445-470.
25. Butler R, MacDonald TM, Struthers AD, Morris AD. Clinical implications of diabetic heart disease. Eur Heart J. 1998;19:1617-1627.
26. O'Keefe JH Jr, Miles JM, Harris WH, Moe RM, McCallister BD. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc. 1999;74:171-180.
27. Zarich SW, Nesto RW. Diabetic cardiomyopathy. Am Heart J. 1989;118:1000-1012.
28. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.
29. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56:2214-2219.
30. 123I] metaiodobenzylguanidine. Diabetes. 1992;41:1069-1075.
31. Kurata C, Uehara A, Sugi T, et al. Cardiac autonomic neuropathy in patients with chronic renal failure on hemodialysis. Nephron. 2000;84:312-319.
32. Stanek B, Frey B, Hulsmann M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol. 2001;38:436-442.
33. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392-2397.
34. Suwa M, Otake Y, Moriguchi A, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J. 1997;133:353-358.
35. Takeishi Y, Atsumi H, Fujiwara S, et al. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med. 1997;38:1085-1089.
36. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9-13.
37. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98:2334-2351.
38. 123I- Metaiodobenzylguanidine (MIBG) imaging and heart rate variability analysis to predict the need for implantable cardioverter defibrillator. J Nucl Cardiol. 2003;10:121-131.
39. Inoue H, Zipes DP. Result of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation. 1987;75:877-887.
40. Bonow R, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Ann Intern Med. 1992;117:502-510.